Indication, Usage and Important Safety Information: LOVAZA™ (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce very high (≥500 mg/dL) triglyceride (TG) levels in adult patients.
In individuals with hypertriglyceridemia (HTG), address excess body weight and alcohol intake before initiating any drug therapy. Diet and exercise can be important ancillary measures. Look for and treat diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus. Certain treatments (e.g., estrogen therapy, thiazide diuretics and beta blockers) are sometimes associated with very significant rises in serum triglyceride (TG) levels. Discontinuation of the specific agent may obviate the need for specific drug therapy for HTG.
Consider lipid-regulating agent use only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. Advise patients that lipid-regulating agent use does not reduce the importance of adhering to diet. (See PRECAUTIONS section of full prescribing information.)
In patients with very high TG levels the effect of LOVAZA on the risk of pancreatitis has not been evaluated, nor has its effect on cardiovascular mortality and morbidity been determined.
- LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.
- Before instituting LOVAZA therapy, it should be confirmed that TG levels are consistently abnormal.
- LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.
- The patient’s TG, LDL-C and ALT levels should be monitored periodically during LOVAZA therapy. In some patients, LOVAZA increased LDL-C. LOVAZA therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment.
- Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.
- There are no adequate and well-controlled studies in pregnant women. Use LOVAZA during pregnancy only if the potential benefit justifies the potential risk to the fetus; and use with caution when administering LOVAZA to breastfeeding women.
- LOVAZA was well-tolerated in controlled studies. The most common adverse events reported were: eructation, infection, flu syndrome, dyspepsia, rash, taste perversion, and back pain.
- Please see full prescribing information.
|
Pharmacists: Welcome to LOVAZA.com
High expectations for lowering very high triglycerides
In the treatment of very high triglycerides (≥500mg/dL)
- LOVAZA dramatically lowered triglycerides by 45%1
- Treatment resulted in a median increase of 45% in LDL-C; treatment with LOVAZA resulted in an overall reduction of atherogenic cholesterol, as reflected by a 14% reduction in non-HDL-C (P=0.0013)1-5
- LOVAZA demonstrates an excellent safety profile and proven tolerability1
- The most common adverse events reported were: eructation, infection, flu syndrome, dyspepsia, rash, taste perversion, and back pain
- LOVAZA is the fastest growing prescription branded triglyceride-lowering agent in the US9
Explore the Pharmacist Corner to learn more about LOVAZA and how it benefits your customers.
The daily dose of LOVAZA is 4 g per day. The daily dose of 4 capsules may be taken all at once or divided into 2 capsules twice daily.1
|
|
Home
About LOVAZA
Cholesterol Guidelines
Pharmacist Corner
Patient Resources
Professional Resources
Prescribing Information
SITE MAP
Indication, Usage and Important Safety Information: LOVAZA™ (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce very high (≥500 mg/dL) triglyceride (TG) levels in adult patients.
In individuals with hypertriglyceridemia (HTG), address excess body weight and alcohol intake before initiating any drug therapy. Diet and exercise can be important ancillary measures. Look for and treat diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus. Certain treatments (e.g., estrogen therapy, thiazide diuretics and beta blockers) are sometimes associated with very significant rises in serum triglyceride (TG) levels. Discontinuation of the specific agent may obviate the need for specific drug therapy for HTG.
Consider lipid-regulating agent use only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. Advise patients that lipid-regulating agent use does not reduce the importance of adhering to diet. (See PRECAUTIONS section of full prescribing information.)
In patients with very high TG levels the effect of LOVAZA on the risk of pancreatitis has not been evaluated, nor has its effect on cardiovascular mortality and morbidity been determined.
- LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.
- Before instituting LOVAZA therapy, it should be confirmed that TG levels are consistently abnormal.
- LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.
- The patient’s TG, LDL-C and ALT levels should be monitored periodically during LOVAZA therapy. In some patients, LOVAZA increased LDL-C. LOVAZA therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment.
- Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.
- There are no adequate and well-controlled studies in pregnant women. Use LOVAZA during pregnancy only if the potential benefit justifies the potential risk to the fetus; and use with caution when administering LOVAZA to breastfeeding women.
- LOVAZA was well-tolerated in controlled studies. The most common adverse events reported were: eructation, infection, flu syndrome, dyspepsia, rash, taste perversion, and back pain.
- Please see full prescribing information.
